Swedish Orphan Biovitrum AB (publ)

OM:SOBI Voorraadrapport

Marktkapitalisatie: SEK 99.8b

Swedish Orphan Biovitrum Beheer

Beheer criteriumcontroles 3/4

De CEO Swedish Orphan Biovitrum is Guido Oelkers, benoemd in May2017, heeft een ambtstermijn van 7.5 jaar. De totale jaarlijkse vergoeding van { bedraagt SEK 48.88M, bestaande uit 25.1% salaris en 74.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.12% van de aandelen van het bedrijf, ter waarde SEK 124.11M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.8 jaar en 4 jaar.

Belangrijke informatie

Guido Oelkers

Algemeen directeur

SEK 48.9m

Totale compensatie

Percentage CEO-salaris25.1%
Dienstverband CEO7.5yrs
Eigendom CEO0.1%
Management gemiddelde ambtstermijn5.8yrs
Gemiddelde ambtstermijn bestuur4yrs

Recente managementupdates

Recent updates

Swedish Orphan Biovitrum AB (publ) Just Beat EPS By 95%: Here's What Analysts Think Will Happen Next

Oct 27
Swedish Orphan Biovitrum AB (publ) Just Beat EPS By 95%: Here's What Analysts Think Will Happen Next

Earnings Beat: Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Jul 19
Earnings Beat: Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly

Jun 24
Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly

Here's Why Shareholders May Consider Paying Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) CEO A Little More

May 08
Here's Why Shareholders May Consider Paying Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) CEO A Little More

Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Apr 27
Swedish Orphan Biovitrum AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Investors Still Waiting For A Pull Back In Swedish Orphan Biovitrum AB (publ) (STO:SOBI)

Apr 24
Investors Still Waiting For A Pull Back In Swedish Orphan Biovitrum AB (publ) (STO:SOBI)

Swedish Orphan Biovitrum AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Apr 06
Swedish Orphan Biovitrum AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly

Mar 05
Swedish Orphan Biovitrum (STO:SOBI) Seems To Use Debt Quite Sensibly

Swedish Orphan Biovitrum's (STO:SOBI) Weak Earnings May Only Reveal A Part Of The Whole Picture

Feb 15
Swedish Orphan Biovitrum's (STO:SOBI) Weak Earnings May Only Reveal A Part Of The Whole Picture

Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) Earnings Haven't Escaped The Attention Of Investors

Jan 17
Swedish Orphan Biovitrum AB (publ)'s (STO:SOBI) Earnings Haven't Escaped The Attention Of Investors

Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?

Nov 24
Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?

Is Swedish Orphan Biovitrum (STO:SOBI) Using Too Much Debt?

Jul 07
Is Swedish Orphan Biovitrum (STO:SOBI) Using Too Much Debt?

Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?

Apr 02
Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?

Is Swedish Orphan Biovitrum AB (publ) (STO:SOBI) Trading At A 30% Discount?

Jan 11
Is Swedish Orphan Biovitrum AB (publ) (STO:SOBI) Trading At A 30% Discount?

These 4 Measures Indicate That Swedish Orphan Biovitrum (STO:SOBI) Is Using Debt Reasonably Well

Dec 27
These 4 Measures Indicate That Swedish Orphan Biovitrum (STO:SOBI) Is Using Debt Reasonably Well

Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?

Sep 28
Is Swedish Orphan Biovitrum (STO:SOBI) A Risky Investment?

Is Swedish Orphan Biovitrum (STO:SOBI) Using Too Much Debt?

Jun 26
Is Swedish Orphan Biovitrum (STO:SOBI) Using Too Much Debt?

Analyse CEO-vergoeding

Hoe is Guido Oelkers's beloning veranderd ten opzichte van Swedish Orphan Biovitrum's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

SEK 4b

Jun 30 2024n/an/a

SEK 2b

Mar 31 2024n/an/a

SEK 2b

Dec 31 2023SEK 49mSEK 12m

SEK 2b

Sep 30 2023n/an/a

SEK 3b

Jun 30 2023n/an/a

SEK 3b

Mar 31 2023n/an/a

SEK 3b

Dec 31 2022SEK 47mSEK 11m

SEK 3b

Sep 30 2022n/an/a

SEK 2b

Jun 30 2022n/an/a

SEK 3b

Mar 31 2022n/an/a

SEK 3b

Dec 31 2021SEK 42mSEK 10m

SEK 3b

Sep 30 2021n/an/a

SEK 3b

Jun 30 2021n/an/a

SEK 3b

Mar 31 2021n/an/a

SEK 3b

Dec 31 2020SEK 33mSEK 10m

SEK 3b

Sep 30 2020n/an/a

SEK 3b

Jun 30 2020n/an/a

SEK 3b

Mar 31 2020n/an/a

SEK 4b

Dec 31 2019SEK 33mSEK 10m

SEK 3b

Sep 30 2019n/an/a

SEK 3b

Jun 30 2019n/an/a

SEK 3b

Mar 31 2019n/an/a

SEK 3b

Dec 31 2018SEK 26mSEK 9m

SEK 2b

Sep 30 2018n/an/a

SEK 2b

Jun 30 2018n/an/a

SEK 2b

Mar 31 2018n/an/a

SEK 1b

Dec 31 2017SEK 16mSEK 5m

SEK 1b

Compensatie versus markt: De totale vergoeding ($USD 4.42M ) Guido } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Swedish markt ($USD 2.20M ).

Compensatie versus inkomsten: De vergoeding van Guido is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.


CEO

Guido Oelkers (59 yo)

7.5yrs

Tenure

SEK 48,883,000

Compensatie

Dr. Guido Oelkers is a Director of Dova Pharmaceuticals Inc. since November 12, 2019. Dr. Oelkers has been the Chief Executive Officer and President at Swedish Orphan Biovitrum AB since May 22, 2017. He se...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Guido Oelkers
CEO & President7.5yrsSEK 48.88m0.12%
SEK 124.1m
Henrik Stenqvist
Chief Financial Officer6.3yrsgeen gegevens0.016%
SEK 16.4m
Torbjörn Hallberg
General Counsel & Head of Legal Affairs5.8yrsgeen gegevens0.0089%
SEK 8.9m
Daniel Rankin
Head of Strategy & Corporate Development2.8yrsgeen gegevens0.0029%
SEK 2.9m
Lena Bjurner
Head of Human Resources1.8yrsgeen gegevensgeen gegevens
Armin Reininger
Senior Scientific & Medical Advisor7.8yrsgeen gegevens0.0047%
SEK 4.7m
Norbert Oppitz
Head of International7.1yrsgeen gegevens0.012%
SEK 11.5m
Sofiane Fahmy
Head of Europe5.8yrsgeen gegevens0.0077%
SEK 7.7m
Duane Barnes
Head of North America3.8yrsgeen gegevensgeen gegevens
Mahmood Ladha
Head of Strategic Transformation Operationsno datageen gegevens0.0018%
SEK 1.8m
Christine Wesstrom
Head of Technical Operations2.7yrsgeen gegevens0.0032%
SEK 3.2m
Lydia Abad-Franch
Senior VP1.8yrsgeen gegevensgeen gegevens

5.8yrs

Gemiddelde duur

56.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van SOBI is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.8 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Hans Wigzell
Chairman of Scientific Advisory Board23.8yrsSEK 158.00kgeen gegevens
Helena Saxon
Director13.6yrsSEK 828.00k0.0067%
SEK 6.6m
Anders Ullman
Director1.5yrsSEK 463.00k0.0010%
SEK 998.0k
Stephen O'Rahilly
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Ralf Pettersson
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Stefan Del Prato
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Jonathan Sanders Arch
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Annette Clancy
Independent Chairman10.5yrsSEK 770.00k0.00099%
SEK 988.0k
Staffan Schuberg
Independent Director4.5yrsSEK 827.00k0.0021%
SEK 2.1m
Filippa Stenberg
Director3.5yrsSEK 673.00k0.00017%
SEK 169.7k
Katy Mazibuko
Employee Representative Director1.8yrsgeen gegevens0.0013%
SEK 1.3m
Christophe Bourdon
Independent Director1.5yrsSEK 433.00kgeen gegevens

4.0yrs

Gemiddelde duur

54.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van SOBI wordt beschouwd als ervaren (gemiddelde ambtstermijn 4 jaar).